In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sol-Gel Technologies Ltd.

www.sol-gel.com

Latest From Sol-Gel Technologies Ltd.

IPO Update: Seven In January As Big Returns, Solid's Slip-Up Contribute To Bubble Concerns

Seven biopharma IPOs launched in the US in January with an average return of 52.8%. The most recent was Sol-Gel's on Jan. 31, but the largest was a $128m offering by ARMO. Solid had the most controversial IPO, but it still gave investors a 70.7% return, contributing to the question: Is biotech in a bubble?

Financing Business Strategies

IPOs In Review: Biopharma Offerings Bounced Back In 2017 As Returns Rose

With an average return of 33.2% in 2017, the number of biopharma IPOs that launched last year rose to 42 after falling to 30 in 2016 compared with 62 in 2015. Following a rough fourth quarter for biopharma stocks, will the IPO momentum continue in 2018?

Financing Business Strategies

IPO Update: New Filings Feed Investor Fervor As Biopharma Stocks Rise

IPO launches in the US hit a wall in August, but several biopharma firms recently entered the queue, adding new opportunities for investors to chase the industry's outperforming returns.

Business Strategies Financing

Deals Shaping The Medical Industry, April 2012

The Dealmaking column is a survey of recent transactions, including strategic alliances, mergers & acquisitions, and financings, in the life sciences industries. Deals are listed by the following industry sectors: in vitro diagnostics, pharmaceuticals, medical devices, and research/analytical instrumentation and reagents. All transactions are excerpted from Elsevier's Strategic Transactions database, providing comprehensive transaction coverage from 1991 to the present.

BioPharmaceutical Medical Device
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Drug Delivery
      • Controlled Release
      • Topical Delivery
    • Generic Drugs
  • Therapeutic Areas
  • Dermatology
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Middle East
      • Israel
  • Parent & Subsidiaries
  • Sol-Gel Technologies Ltd.
  • Senior Management
  • Alon Seri-Levy, PhD, CEO
    Gilad Mamlok, CFO
    Ofer Toledano, PhD, VP, R&D
    Ofra Levy-Hacham, PhD, VP, Quality Assurance & Reg. Affairs
  • Contact Info
  • Sol-Gel Technologies Ltd.
    Phone: (972) 8 9313433
    7 Golda Meir St.
    Ness Ziona, 74036
    Israel
Advertisement
Advertisement
UsernamePublicRestriction

Register